Glivec 100 mg film-coated tablets
Product Information *
Company:
Novartis Ireland LimitedStatus:
No Recent UpdateActive Ingredients :
This medicinal product is subject to additional monitoring.
*Additional information is available upon request
Legal Category:
Product subject to medical prescription which may not be renewed (A)
When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.
Updated on 07 May 2021
File name
Glivec-N-123 REGPIL PF21-0098_Clean_19.04.2021_1620393898.pdf
Reasons for updating
- Individual PILs superseded by joint PIL
Updated on 01 July 2020
File name
IPHA Glivec FCT REGPIL PF 20-0128_Clean_1593601029.pdf
Reasons for updating
- Change to section 2 - pregnancy, breast feeding and fertility
Updated on 01 July 2020
File name
Glivec FCT REGSPC PF 20-0128_Clean _1593599482.pdf
Reasons for updating
- Change to section 4.6 - Pregnancy and lactation
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 07 April 2020
File name
Glivec_100mg_REG PIL PF 19-0236 BRAIN Clean IPHA Aug 2019_1586253551.pdf
Reasons for updating
- Change to name of manufacturer
Updated on 23 August 2019
File name
Glivec 100mg FCT Package Leaflet April 2019_1554377577.pdf
Reasons for updating
- Change to section 6 - date of revision
Updated on 04 April 2019
File name
Glivec 100mg FCT Package Leaflet April 2019_1554377577.pdf
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
Updated on 04 April 2019
File name
Glivec_100mg_400mg_FCTab_28-Mar-19_English_Clean _1554377309.pdf
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may not be renewed (A)
Updated on 20 July 2018
File name
REG_PIL_Glivec 100mg FCT_R91_WEH_p1_LFT_X-4_IPHA.pdf
Reasons for updating
- Change to section 2 - what you need to know - warnings and precautions
- Change to section 4 - possible side effects
- Change to section 6 - marketing authorisation holder
- Change to section 6 - date of revision
Updated on 21 February 2017
File name
PIL_8510_811.pdf
Reasons for updating
- New PIL for new product
Updated on 21 February 2017
Reasons for updating
- Change to section 4 - possible side effects
Updated on 22 June 2016
Reasons for updating
- Change to warnings or special precautions for use
Updated on 08 May 2015
Reasons for updating
- Change to side-effects
Updated on 29 April 2015
Reasons for updating
- Change to warnings or special precautions for use
- Addition of black triangle
Updated on 23 April 2014
Reasons for updating
- Change to warnings or special precautions for use
Updated on 30 July 2013
Reasons for updating
- Change to date of revision
Updated on 27 September 2012
Reasons for updating
- Change to warnings or special precautions for use
- Change to drug interactions
- Change to MA holder contact details
Updated on 30 August 2011
Reasons for updating
- Change to side-effects
Updated on 10 April 2007
Reasons for updating
- Change to warnings or special precautions for use
- Change to, or new use for medicine
Updated on 10 January 2007
Reasons for updating
- Change to, or new use for medicine
Updated on 12 July 2006
Reasons for updating
- Change to side-effects
Updated on 02 November 2005
Reasons for updating
- Change to side-effects
- Change to dosage and administration
Updated on 25 August 2004
Reasons for updating
- New PIL for medicines.ie